IN RECENT years, penicillamine has become an important drug in the treatment of patients with rheumatoid arthritis. Unfortunately, in approximately 35% of these individuals, severe side effects will develop, requiring withdrawal of the drug therapy. 1 Cutaneous, renal, and hematologic abnormalities are the most commonly recognized untoward effects. Recently, myasthenia gravis associated with penicillamine treatment has been reported. 2 A clear temporal relationship suggestive of a drug-induced effect between this neuromuscular syndrome and the administration of penicillamine and the resolution of symptoms after withdrawal of the drug therapy have been observed in most patients. In this report, we describe a patient whose myasthenic symptoms resolved after discontinuation of the drug treatment but spontaneously recurred six months later. We also discuss the possible mechanisms of penicillamine-induced myasthenia gravis. Report of a Case Rheumatoid arthritis developed in a 54-year-old man in 1972. He did well while receiving aspirin until March 1978, when
[1]
T. Anastassiades,et al.
The toxicity pattern of d-penicillamine therapy
,
1980
.
[2]
N. Farid,et al.
A study of human leukocyte D locus related antigens in Graves' disease.
,
1979,
The Journal of clinical investigation.
[3]
J. Ward,et al.
Ptosis and weakness after start of D-penicillamine therapy.
,
1978,
Annals of internal medicine.
[4]
P. Halverson,et al.
Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis.
,
1978,
JAMA.
[5]
C. Masters,et al.
Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies.
,
1977,
The American journal of medicine.
[6]
P. Zilko,et al.
Letter: Penicillamine therapy, antistriational antibody, and myasthenia gravis.
,
1975,
British medical journal.